Oral beta-blockers for mild to moderate hypertension during pregnancy (Review)

Magee L, Duley L

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 8

http://www.thecochranelibrary.com

WILEY Publishers Since 1807
Oral beta-blockers for mild to moderate hypertension during pregnancy

Laura Magee¹, Lelia Duley²

¹Departments of Internal Medicine (UBC) and Specialized Women’s Health (BC Women’s Hospital), British Columbia Women’s Hospital and Health Centre, Vancouver, Canada. ²Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK

Contact address: Laura Magee, Departments of Internal Medicine (UBC) and Specialized Women’s Health (BC Women’s Hospital), British Columbia Women’s Hospital and Health Centre, 4500 Oak Street, Suite 1U59, Vancouver, British Columbia, V6H 3N1, Canada. lmagee@cw.bc.ca.

Editorial group: Cochrane Pregnancy and Childbirth Group.

Publication status and date: Edited (no change to conclusions), published in Issue 8, 2012.

Review content assessed as up-to-date: 30 January 2004.

Citation: Magee L, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD002863. DOI: 10.1002/14651858.CD002863.

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Antihypertensives, such as beta-blockers, are used for pregnancy hypertension in the belief these will improve outcome for mother and baby.

Objectives

To assess whether oral beta-blockers are better than placebo, or no beta-blocker, and have advantages over other antihypertensives, for women with mild to moderate pregnancy hypertension.

Search methods

We searched the Cochrane Pregnancy and Childbirth Group trials register (January 2004) and bibliographies of retrieved papers and personal files. We updated this search on 4 July 2012 and added the results to the awaiting classification section of the review.

Selection criteria

Trials comparing beta-blockers with placebo or no therapy, or other antihypertensives, for women with mild to moderate pregnancy hypertension.

Data collection and analysis

We extracted the data independently and were not blinded to trial characteristics or outcomes. Whenever possible, we contacted authors for missing data.

Main results

Twenty-nine trials (approximately 2500 women) are included. Thirteen trials (1480 women) compared beta-blockers with placebo/no beta blocker. Oral beta-blockers decrease the risk of severe hypertension (relative risk (RR) 0.37, 95% confidence interval (CI) 0.26 to 0.53; 11 trials, N = 1128 women) and the need for additional antihypertensives (RR 0.44, 95% CI 0.31 to 0.62; 7 trials, N = 856 women). There are insufficient data for conclusions about the effect on perinatal mortality or preterm birth. Beta-blockers seem to be associated with an increase in small-for-gestational-age (SGA) infants (RR 1.36, 95% CI 1.02 to 1.82; 12 trials; N = 1346...
women). Maternal hospital admission may be decreased, neonatal bradycardia increased and respiratory distress syndrome decreased, but these outcomes are reported in only a small proportion of trials. In 13 trials (854 women), beta-blockers were compared with methyldopa. Beta-blockers appear to be no more effective and probably equally as safe. Single small trials have compared beta-blockers with hydralazine, nicardipine or isradipine. It is unusual for women to change drugs due to side effects.

Authors’ conclusions

Improvement in control of maternal blood pressure with use of beta-blockers would be worthwhile only if it were reflected in substantive benefits for mother and/or baby, and none have been clearly demonstrated. The effect of beta-blockers on perinatal outcome is uncertain; the worrying trend to an increase in SGA infants is partly dependent on one small outlying trial. Large randomised trials are needed to determine whether antihypertensive therapy in general (rather than beta-blocker therapy specifically) results in greater benefit than risk, for treatment of mild-moderate pregnancy hypertension. If so, then it would be appropriate to consider which antihypertensive is best, and beta-blockers should be evaluated.

[Note: the seventeen reports in the awaiting classification section of the review may alter the conclusions of the review once assessed.]

PLAIN LANGUAGE SUMMARY

Oral beta-blockers for mild to moderate hypertension during pregnancy

Pregnant women with mild to moderate hypertension taking beta-blockers have reduced blood pressure, but these drugs may have adverse effects on the baby.

While very high blood pressure (hypertension) in pregnancy can damage blood vessel walls and lead to serious complications, small rises in blood pressure may do little harm. The blood pressure level at which treatment should be started in pregnancy is not known. Beta-blocker drugs cause the heart to beat more slowly and less forcefully, reducing pressure on blood vessels. This review of trials found that pregnant women with mild to moderate hypertension who take beta-blockers have lower blood pressure, but the baby may grow more slowly than expected. There is not enough evidence on other effects. Further research is needed.